InvestorsObserver
×
News Home

Tcr2 Therapeutics Inc (TCRR) Stock: What Does the Chart Say Monday?

Monday, September 26, 2022 03:49 PM | InvestorsObserver Analysts

Mentioned in this article

Tcr2 Therapeutics Inc (TCRR) Stock: What Does the Chart Say Monday?

Tcr2 Therapeutics Inc (TCRR) stock has fallen 18.60% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
Tcr2 Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on TCRR!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With TCRR Stock Today?

Tcr2 Therapeutics Inc (TCRR) stock is trading at $1.75 as of 3:48 PM on Monday, Sep 26, a drop of -$0.11, or -5.91% from the previous closing price of $1.86. The stock has traded between $1.72 and $1.91 so far today. Volume today is 203,652 compared to average volume of 237,080. To screen for more stocks like Tcr2 Therapeutics Inc click here.

More About Tcr2 Therapeutics Inc

TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which is effective in patients with solid tumors. Click Here to get the full Stock Report for Tcr2 Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App